Skip to main content

Cannabis Use Disorder

5
Pipeline Programs
4
Companies
13
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
5
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
4 programs
4
Broad Spectrum CannabidiolPhase 21 trial
Broad Spectrum CannabidiolPhase 21 trial
Cannabidiol - fsCBDPhase 21 trial
Dronabinol PillPhase 21 trial
Active Trials
NCT06569394Recruiting200Est. Jun 2028
NCT06575751Recruiting120Est. Jun 2028
NCT06107062Recruiting165Est. Mar 2029
+1 more trials
Aelis Farma
Aelis FarmaFrance - Bordeaux
1 program
1
AEF0117Phase 25 trials
Active Trials
NCT06395688Withdrawn0Est. Jun 2026
NCT05451017Terminated22Est. Jun 2023
NCT05554926Completed8Est. Feb 2023
+2 more trials
Applied Medical
Applied MedicalCA - Rancho Santa Margarita
1 program
Abstinence-focused Contingency ManagementN/A1 trial
Active Trials
NCT05836207Recruiting154Est. Sep 2027
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
CUD-AMTN/A1 trial
Active Trials
NCT03432013Completed51Est. Jun 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Colorado TherapeuticsBroad Spectrum Cannabidiol
Colorado TherapeuticsBroad Spectrum Cannabidiol
Colorado TherapeuticsDronabinol Pill
Colorado TherapeuticsCannabidiol - fsCBD
Aelis FarmaAEF0117
Aelis FarmaAEF0117
Aelis FarmaAEF0117
Aelis FarmaAEF0117
Aelis FarmaAEF0117
Aelis FarmaAEF0117
Aelis FarmaAEF0117
Applied MedicalAbstinence-focused Contingency Management
Angeles TherapeuticsCUD-AMT

Clinical Trials (13)

Total enrollment: 1,174 patients across 13 trials

NCT06569394Colorado TherapeuticsBroad Spectrum Cannabidiol

A Study of Cannabidiol in Young Adult Cannabis Users

Start: Dec 2024Est. completion: Jun 2028200 patients
Phase 2Recruiting
NCT06575751Colorado TherapeuticsBroad Spectrum Cannabidiol

Cannabidiol and Cannabis Concentrate Users

Start: Dec 2024Est. completion: Jun 2028120 patients
Phase 2Recruiting

Effects of THC on Alcohol Consumption and Neural Correlates of Reward

Start: Jul 2024Est. completion: Jun 202628 patients
Phase 2Recruiting

Longitudinal Outpatient Treatment for Cannabis Use Disorder

Start: May 2024Est. completion: Mar 2029165 patients
Phase 2Recruiting

Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

Start: May 2022Est. completion: Jul 2024333 patients
Phase 2Completed

Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects

Start: Oct 2018Est. completion: Jan 202129 patients
Phase 2Completed

Drug-Drug Interaction Between THC and AEF0117

Start: Dec 2025Est. completion: Jun 20260
Phase 1Withdrawn

The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers

Start: Jan 2023Est. completion: Jun 202322 patients
Phase 1Terminated

Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects

Start: Dec 2022Est. completion: Feb 20238 patients
Phase 1Completed

Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

Start: Jan 2018Est. completion: May 201824 patients
Phase 1Completed

Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

Start: Apr 2017Est. completion: Feb 201840 patients
Phase 1Completed
NCT05836207Applied MedicalAbstinence-focused Contingency Management

Rewards for Cannabis Abstinence-study

Start: Nov 2023Est. completion: Sep 2027154 patients
N/ARecruiting

Affective Management Training for Cannabis Misuse

Start: Feb 2018Est. completion: Jun 202151 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 actively recruiting trials targeting 1,174 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.